Parkinson's Drug Reduces Disease Markers in Breakthrough Trial
ScienceAlert
|
Contributed by: Reid Stephan
Summary
A novel therapy developed by Vaxxinity, codenamed UB-312, is showing promise in early clinical trials for treating Parkinson’s disease by targeting and reducing toxic clumps of alpha-synuclein protein in cerebrospinal fluid, a key factor believed to drive the disease's progression. This groundbreaking approach marks a significant advancement in the potential treatment and prevention of Parkinson's, offering hope for disease-modifying treatment. Early trial results suggest that UB-312 can lower levels of harmful protein aggregates, which may lead to improved motor function in patients. While the therapy is still under investigation and requires further testing to confirm its safety and efficacy, it represents a hopeful development for the nearly one million Americans currently diagnosed with Parkinson’s and those who will be diagnosed in the future.
